Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized phase II trial of concurrent chemoradiation with cetuximab (Erbitux), 5 fluorouracil, hydroxyurea [hydroxycarbamide], and twice-daily radiation (CetuxFHX) versus cetuximab (Erbitux), cisplatin and accelerated radiation with concomitant boost (CetuxPX) after induction chemotherapy in patients with locally advanced head and neck cancer

Next Previous
X
Search
Trial Profile

A randomized phase II trial of concurrent chemoradiation with cetuximab (Erbitux), 5 fluorouracil, hydroxyurea [hydroxycarbamide], and twice-daily radiation (CetuxFHX) versus cetuximab (Erbitux), cisplatin and accelerated radiation with concomitant boost (CetuxPX) after induction chemotherapy in patients with locally advanced head and neck cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin; Fluorouracil; Hydroxycarbamide
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Acronyms EPIC

    • Most Recent Events

    • 20 Sep 2019 Status changed from active, no longer recruiting to completed.
    • 09 Oct 2012 Planned End Date changed from 1 Jul 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Results were presented at the 47th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top